XML 28 R11.htm IDEA: XBRL DOCUMENT
v3.26.1

Cash, Cash Equivalents, and Investments | 3 Months Ended
--- | ---
Apr. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Cash, Cash Equivalents, and Investments | Cash, Cash Equivalents, and Investments Cash, cash equivalents, and investments consisted of the following as of the dates indicated (in thousands):
| April 30, 2026 |  | January 31, 2026
Cash and cash equivalents: |  |  |
Cash | $ | 57,231 |  |  | $ | 51,006 |
Money market funds | 150,653 |  |  | 185,205 |
Commercial paper | 996 |  |  | 1,191 |
Total cash and cash equivalents | $ | 208,880 |  |  | $ | 237,402 |
Available-for-sale investments: |  |  |
U.S. Treasury securities | $ | 61,440 |  |  | $ | 60,429 |
Commercial paper | 5,182 |  |  | 2,218 |
Corporate debt securities | 141,566 |  |  | 143,490 |
U.S. Government agency securities | 26,889 |  |  | 26,299 |
Total available-for-sale investments | $ | 235,077 |  |  | $ | 232,436 |
The following tables summarize the amortized cost, net unrealized gains (losses), and fair value of the Company’s investments by significant investment category as of the dates indicated (in thousands). Gross realized gains or losses from sales of available-for-sale securities were not material for the three months ended April 30, 2026 and 2025.
| April 30, 2026
| Amortized Cost |  | Unrealized Gain (Loss), Net |  | Estimated Fair Value
Available-for-sale investments: |  |  |  |  |
U.S. Treasury securities | $ | 61,467 |  |  | $ | (27) |  |  | $ | 61,440 |
Commercial paper | 5,183 |  |  | (1) |  |  | 5,182 |
Corporate debt securities | 141,775 |  |  | (209) |  |  | 141,566 |
U.S. Government agency securities | 26,906 |  |  | (17) |  |  | 26,889 |
Total available-for-sale investments | $ | 235,331 |  |  | $ | (254) |  |  | $ | 235,077 |
| January 31, 2026
| Amortized Cost |  | Unrealized Gain (Loss), Net |  | Estimated Fair Value
Available-for-sale investments: |  |  |  |  |
U.S. Treasury securities | $ | 60,357 |  |  | $ | 72 |  |  | $ | 60,429 |
Commercial paper | 2,218 |  |  | — |  |  | 2,218 |
Corporate debt securities | 143,257 |  |  | 233 |  |  | 143,490 |
U.S. Government agency securities | 26,283 |  |  | 16 |  |  | 26,299 |
Total available-for-sale investments | $ | 232,115 |  |  | $ | 321 |  |  | $ | 232,436 |
The following tables present the Company’s available-for-sale securities by contractual maturity date as of the dates indicated (in thousands):
| April 30, 2026
| Amortized Cost |  | Fair Value
Due within one year | $ | 139,776 |  |  | $ | 139,819 |
Due between one to five years | 95,555 |  |  | 95,258 |
Total | $ | 235,331 |  |  | $ | 235,077 |
| January 31, 2026
| Amortized Cost |  | Fair Value
Due within one year | $ | 142,032 |  |  | $ | 142,237 |
Due between one to five years | 90,083 |  |  | 90,199 |
Total | $ | 232,115 |  |  | $ | 232,436 |
As of April 30, 2026, there were 89 securities in an unrealized loss position with an aggregate fair value of $146.4 million, none of which were in a continuous unrealized loss position for more than 12 months. As of January 31, 2026, there were 43 securities in an unrealized loss position with an aggregate fair value of $64.6 million, none of which was in a continuous unrealized loss position for more than 12 months. When evaluating investments for impairment, the Company reviews factors such as the extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, and the Company’s intent to sell, or whether it is more likely than not that the Company will be required to sell, the investment before recovery of the investment’s amortized cost. No impairment loss has been recorded on the securities included in the tables above, as the Company believes that any decrease in fair value of these securities is temporary and the Company expects to recover at least up to the initial cost of the investment for these securities. The Company has not recorded an allowance for credit losses, as the Company believes any such losses would not be material based on the high-grade credit rating for each of its marketable securities as of the end of each period.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration